ClinicalTrials.Veeva

Menu

Pepsin As A Biomarker For Aspiration

Medical College of Wisconsin logo

Medical College of Wisconsin

Status

Completed

Conditions

Gastroesophageal Reflux
Aspiration

Treatments

Procedure: Tracheal Lavage

Study type

Observational

Funder types

Other

Identifiers

NCT00865995
GC 636
CHW 08/26

Details and patient eligibility

About

Evaluation of tracheal pepsin as a biomarker for aspiration

Full description

Aspiration is well recognized in children who have chronic lung disease or who are intubated. There is a known association between gastroesophageal reflux (GER) and aspiration. The distinction between aspiration of swallowed material, such as food and the aspiration of refluxed gastric contents is important. Determining whether an aspiration syndrome in an individual is due to GER may be difficult. The most widely used test to determine whether GER is the cause of aspiration involves staining bronchoalveolar lavage (BAL) fluid for lipid laden macrophages (LLM) based on the hypothesis that refluxed and aspirated fluid is phagocytosed by tracheal macrophages.

Pepsinogen is a protein unique to gastric chief cells and also requires acidic conditions for activation. Therefore the presence of pepsin in BAL fluid should only be found when gastric fluid is aspirated. In previous studies, pepsin has been detected in the tracheal fluid of children with chronic lung disease. Thus far, studies of this material have been small, not all have control groups, and LLM were not looked for in all studies.

Based on previous studies and the need to improve diagnostic methods, the following aims are proposed:

  1. to determine the frequency of pepsin contamination of children without chronic respiratory disease undergoing elective surgery with intubation
  2. to determine frequency of tracheal pepsin and lipid laden macrophages (LLM) in children with chronic respiratory disease or symptoms and in children with tracheostomies
  3. to compare the presence or absence and concentration of pepsin to the presence of LLM
  4. to relate the presence or absence and concentration of pepsin to clinical status To achieve these aims, BAL fluid will be obtained from subject patients and controls. These fluids will be transported to the research lab and stored on ice until analysis. Determination of LLM will be done in children undergoing diagnostic bronchoscopy in the clinical lab of CHW per routine. BAL analysis will consist of Western blot staining for the presence of pepsin. Demographic data will also be collected from the medical record.

Enrollment

76 patients

Sex

All

Ages

1 to 18 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Meet criteria of study population

Exclusion criteria

  • Lack of informed consent/assent
  • Pulmonary disease in normal controls

Trial design

76 participants in 3 patient groups

1
Description:
patients undergoing elective procedures with intubation and no known respiratory pathology
Treatment:
Procedure: Tracheal Lavage
2
Description:
patients with tracheostomy
3
Description:
patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems